Status:
RECRUITING
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Leukopenia
Neutropenia
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
Background: * WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is caused by various genetic changes that increase the activity of the chemokine receptor, CXCR4. Excessive ...
Detailed Description
Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplant...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- All of the following inclusion criteria must be met for a subject to be enrolled in this study:
- Clinical diagnosis of WHIMS and documented severe infection
- Must be greater than or equal to 18 and less than or equal to 75 years of age
- Willingness to interrupt medications to raise the white count (WBC) such as G-CSF or GM-CSF for at least 2 days before and while on the study drug
- Must not be pregnant or breastfeeding
- Must have a personal physician
- Must be willing to provide blood, plasma, serum, and DNA samples for storage
- Subjects must agree not to become pregnant or to impregnate a female. If of childbearing potential, must agree to consistently use two types of contraception throughout study participation. Acceptable forms of contraception include the following:
- Condoms, male or female, with or without a spermicide
- Diaphragm or cervical cap with spermicide
- Intrauterine device
- Contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved contraceptive method
- Male partner has previously undergone a vasectomy for which there is documentation of aspermatogenic sterility
- EXCLUSION CRITERIA:
- If any of the following exclusion criteria are met, a subject will not be enrolled in this study:
- Absence of a diagnosis of WHIMS
- Patient is less than 18 years old
- Absence of a documented history of severe infection
- Neutropenia due to maturation defects in the myeloid lineage or that the PI feels is unlikely to benefit from this medication
- Pregnant women or breastfeeding
- History of serious cardiac arrhythmia or cardiac defects that make such more likely
- Renal failure (calculated creatinine clearance \[CrCl\] \<15 mL/min or requiring dialysis)
- Signs or symptoms of active microbial infection at the time of study entry.
- Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study
- Unwillingness to undergo testing or procedures associated with this protocol
Exclusion
Key Trial Info
Start Date :
January 6 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00967785
Start Date
January 6 2010
End Date
April 30 2026
Last Update
December 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892